What is in the dispatch?

New randomised trials and pooled analyses with their participant counts and effect sizes, trials that passed their completion date without posting results, retractions, and the comparator and funding details that get dropped from headlines. Every item carries its PubMed ID or trial registry number so you can check it.

Is anything being sold?

No. There are no affiliate links, no discount codes, no sponsored items and no vendor recommendations anywhere on this site or in the dispatch. That is deliberate, because a null result has to be as publishable as a positive one for any of this to be worth reading.

Where do the items come from?

A script scans PubMed and ClinicalTrials.gov across every compound in the catalogue for anything new in the window, ranks randomised trials, meta-analyses and retractions first, and returns the records. Each record is then read at the source before it goes in an issue. Nothing is included on the strength of a press release.

Can I read past issues without subscribing?

Yes. Every issue is published in full on this site as a permanent article with its citations and links into the compound profiles. The archive is below and there is no paywall on any of it.

The Dispatch

What changed in the evidence, every other week

Most newsletters in this field forward press releases. A press release is a company describing its own trial before anyone can inspect it, which is the weakest form of evidence that still counts as news. This one is built by scanning PubMed and the trial registries across all 281 compounds documented here, reading the records that come back, and reporting them with their identifiers attached.

Which means it reports absences too. A phase 3 trial that passed its completion date and posted no results is real news, because it tells you the data exists and you cannot see it. The first issue is largely about exactly that.

Every other week, on a Saturday. Your address is used for the dispatch and nothing else. One click unsubscribes and there is no sequence, no upsell and nothing for sale.

What an issue actually contains

Trials that finished, and trials that finished without telling anyone

Every fortnight the whole catalogue is scanned against ClinicalTrials.gov for status changes. A phase 3 trial that passed its completion date and posted no results is news, because it means the data exists and you cannot see it yet. That is the kind of thing a press release will never tell you.

New randomised trials and pooled analyses, with the numbers

PubMed is scanned across every compound here, and randomised trials, meta-analyses and retractions are read first. Each item comes with its participant count, its effect size and its identifier, so you can check it rather than take it.

The comparator, the dose and who paid

A head to head against a rival drug's lowest dose is a different claim than one against its best dose, and that qualifier vanishes by the time a finding becomes a headline. Funding gets named in both directions, including when a null result was funded by someone with an interest in a null.

Retractions and corrections, including ours

Papers get withdrawn and this field keeps citing them for years afterwards. When a study behind a claim on this site is retracted or corrected, the issue says so and the page gets fixed. When we get something wrong, that goes in too.

Nothing for sale

No affiliate links, no discount codes, no sponsored items, no vendor recommendations. There is nothing to buy here and no revenue attached to what an issue says, which is the only arrangement under which a null result is as publishable as a positive one.

If a fortnight passes with nothing worth your time, the issue will be two lines long and say so. A newsletter that is always interesting in a field where genuine developments are not on a schedule is a newsletter that has started making things up.

Every issue, in full, free

Issue 001Sep 12, 2026
Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
A CagriSema versus tirzepatide phase 3 completed in July at a tirzepatide dose that flatters the sponsor. Five retatrutide phase 3 trials covering 6,415 people have hit their primary completion dates with no results posted. And 378 randomised trials ranked what actually prevents diabetes.
Read the issue

Questions people ask about this

What is in the dispatch?: New randomised trials and pooled analyses with their participant counts and effect sizes, trials that passed their completion date without posting results, retractions, and the comparator and funding details that get dropped from headlines. Every item carries its PubMed ID or trial registry number so you can check it.
How often does it arrive?: Every other week, on a Saturday. If a fortnight passes with nothing worth your time, the issue will be short and say so rather than padding itself out.
Is anything being sold?: No. There are no affiliate links, no discount codes, no sponsored items and no vendor recommendations anywhere on this site or in the dispatch. That is deliberate, because a null result has to be as publishable as a positive one for any of this to be worth reading.
Where do the items come from?: A script scans PubMed and ClinicalTrials.gov across every compound in the catalogue for anything new in the window, ranks randomised trials, meta-analyses and retractions first, and returns the records. Each record is then read at the source before it goes in an issue. Nothing is included on the strength of a press release.
Can I read past issues without subscribing?: Yes. Every issue is published in full on this site as a permanent article with its citations and links into the compound profiles. The archive is below and there is no paywall on any of it.